5Munoz-Price LS,Weinstein RA. Acinetobacter infection[J].New England Journal of Medicine,2008,(12):1271-1281.doi:10.1056/NEJMra070741.
6Clinical and Laboratory Standards Institute. M 100-S18,Performance standards for antimicrobial susceptibility testing.Eighteenth informational supplement[S].CLSI,2008.
7Wang FD,Cho WL,Liu CY. Risk factors for mortality in patients with Acinetobacter baummannii bloodstream infection with genotypic species identification[J].Journal of Microbiology Immunology and Infection,2008,(05):397-402.
8Alejandro Beceiro,Astrid Pérez,Felipe Femández-Cuenca. Genetic variability among ampC genes from acinetobacter genomic species[J].Antimicrobial Agents and Chemotherapy,2009,(03):1177-1184.doi:10.1128/AAC.00485-08.
9Yang CH,Lee S,Su PW. Genotype and antibiotic susceptibility patterns of drug-resistant pseudomonas aeruginosa and acinetobacter baumanaii isolates in Taiwan[J].Microbial Drug Resistance-Mechanisms Epidemiology and Disease,2008,(04):281-288.
10Higgins PG,Wisplinghoff H,Stefanik D. In vitro activities of β-lactamase inhibitors clavulanic acid,sulbactam,and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J].Antimicrobial Agents and Chemotherapy,2004,(05):1586-1592.doi:10.1128/AAC.48.5.1586-1592.2004.
